“Data show incorporating iStent Infinite with cataract surgery, with or without iDose TR, significantly lowers IOP and reduces topical medication needs,” said Dr. Lisa Feulner in her presentation.
Nathan M. Radcliffe, MD, Editor, Glaucoma Physician, and Sean Ianchulev, MD, MPH, New York Eye and Ear of Mount Sinai, discuss whether addressing both trabecular and uveoscleral pathways could improve outcomes in moderate to advanced disease.